Skip to main content

ASCPT 2024 Annual Meeting Main banner

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

M
LB-017
MACHINE LEARNING MODELING TO PREDICT INFLIXIMAB PHARMACOKINETICS IN PEDIATRIC PATIENTS WITH CROHN'S DISEASE

Favorite
AI-007
MACHINE LEARNING MODELING TO PREDICT INFLIXIMAB PHARMACOKINETICS IN PEDIATRIC PATIENTS WITH CROHN'S DISEASE

Favorite
PII-209
MEDICAL SUPPLY TRANSPORT TO EVACUATION SHELTERS BY DRONE: PROPOSAL OF OITA MODEL USING RENDEZVOUS POINTS OF AIR AMBULANCE.

Favorite
PII-123
METABOLIC PROFILING OF ECOPIPAM

Favorite
PII-124
METABOLISM AND DISPOSITION OF [14C]-ONC201 (DORDAVIPRONE) IN HEALTHY ADULT PARTICIPANTS

Favorite
PII-125
MICRODOSING APPROACH TO EVALUATE WHETHER ECOPIPAM AFFECTS DRUG METABOLISM AND TRANSPORT OF CONCOMITANT MEDICATIONS

Favorite
PT-018
MINIMAL SAMPLING TO ASSESS MECHANISMS LINKING IMMUNE CHECKPOINT INHIBITOR PHARMACOKINETICS AND OUTCOMES IN CANCER PATIENTS

Favorite
PWII-003
MINIMAL SAMPLING TO ASSESS MECHANISMS LINKING IMMUNE CHECKPOINT INHIBITOR PHARMACOKINETICS AND OUTCOMES IN CANCER PATIENTS

Favorite
PII-081
MISS SCORES VARY IN ACCORDANCE WITH SLCO1B1 STATUS IN A COHORT OF JIA PATIENTS

Favorite
LB-018
MODEL BASED META ANALYSIS OF IMATINIB PHARMACOKINETICS: IN ABCB1, ABCG2, AND CYP3A5 GENOTYPES.

Favorite
PII-126
MODEL-BASED META-ANALYSIS (MBMA) OF OBJECTIVE RESPONSE RATE (ORR) AND GRADE 3+ TREATMENT-RELATED ADVERSE EVENTS (G3TRAE) IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC).

Favorite
PII-058
MODEL-BASED META-ANALYSIS (MBMA) OF OBJECTIVE RESPONSE RATE (ORR), PROGRESSION-FREE SURVIVAL (PFS), AND OVERALL SURVIVAL (OS) TO COMPARE PD-1 AND PD-L1 TREATMENT OUTCOMES IN METASTATIC (M) NON-SMALL-CELL LUNG CANCER (NSCLC)

Favorite
PWII-001
MODEL-BASED META-ANALYSIS (MBMA) OF OBJECTIVE RESPONSE RATE (ORR), PROGRESSION-FREE SURVIVAL (PFS), AND OVERALL SURVIVAL (OS) TO COMPARE PD-1 AND PD-L1 TREATMENT OUTCOMES IN METASTATIC (M) NON-SMALL-CELL LUNG CANCER (NSCLC)

Favorite
PII-004
MODEL-BASED REPRIMING WINDOW SELECTION FOR SUBCUTANEOUS EPCORITAMAB.

Favorite
LB-019
MODEL-INFORMED DOSE OPTIMIZATION FOR PROPHYLACTIC PIPERACILLIN-TAZOBACTAM IN PERIOPERATIVE PEDIATRIC PATIENTS.

Favorite
LB-020
MODEL-INFORMED DRUG DEVELOPMENT APPROACH FOR APPROVAL OF INTRAVENOUS FORMULATION OF SECUKINUMAB IN PSORIATIC ARTHRITIS (PSA), ANKYLOSING SPONDYLITIS (AS) AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA)

Favorite
E-002
MODEL-INFORMED PRECISION DOSING GUIDANCE OF ETHOSUXIMIDE DEVELOPED FROM A RANDOMIZED CONTROLLED CLINICAL TRIAL OF CHIILDHOOD ABSENCE EPILEPSY.

Favorite
PII-127
MODELING AND SIMULATION TO EXPLORE MECHANISMS OF PHARMACOKINETIC DRUG-DRUG INTERACTIONS OF ABEMACICLIB AND OLAPARIB IN PATIENTS WITH RECURRENT PLATINUM-RESISTANT OVARIAN CANCER

Favorite
PII-059
MODELING M-PROTEIN DYNAMICS IN SUBJECTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING VENETOCLAX: UTILITY OF EARLY M-PROTEIN MONITORING TO PREDICT PROGRESSION FREE SURVIVAL

Favorite
LB-021
MORPHINE-METABOLITE POPULATION PHARMACOKINETIC MODELING IN NEONATES WITH NEONATAL OPIOID WITHDRAWAL SYNDROME FOLLOWING ORAL ADMINISTRATION OF MORPHINE.

Favorite
LB-022
MULTIPLE ELIMINATION PATHWAYS ARE RESPONSIBLE FOR THE ELIMINATION OF ETRUMADENANT (ETRUMA) AFTER ORAL ADMINISTRATION OF [14C]-ETRUMA TO HUMANS.

Favorite